Checchi Capital Advisers LLC lessened its stake in Merck & Company, Inc. (NYSE:MRK) by 0.6% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 29,388 shares of the company’s stock after selling 185 shares during the period. Checchi Capital Advisers LLC’s holdings in Merck & were worth $1,883,000 at the end of the most recent quarter.
A number of other institutional investors also recently added to or reduced their stakes in MRK. Canada Pension Plan Investment Board boosted its position in Merck & by 70.4% in the 1st quarter. Canada Pension Plan Investment Board now owns 5,568,791 shares of the company’s stock worth $353,841,000 after purchasing an additional 2,300,200 shares in the last quarter. AQR Capital Management LLC boosted its position in Merck & by 23.7% in the 1st quarter. AQR Capital Management LLC now owns 8,146,594 shares of the company’s stock worth $517,635,000 after purchasing an additional 1,561,853 shares in the last quarter. Karp Capital Management Corp purchased a new stake in Merck & in the 1st quarter worth approximately $94,200,000. CIBC World Markets Inc. boosted its position in Merck & by 536.0% in the 1st quarter. CIBC World Markets Inc. now owns 1,290,373 shares of the company’s stock worth $81,990,000 after purchasing an additional 1,087,497 shares in the last quarter. Finally, Independent Franchise Partners LLP boosted its position in Merck & by 12.4% in the 2nd quarter. Independent Franchise Partners LLP now owns 9,250,317 shares of the company’s stock worth $592,852,000 after purchasing an additional 1,020,630 shares in the last quarter. Institutional investors and hedge funds own 72.86% of the company’s stock.
Several equities research analysts have commented on MRK shares. Jefferies Group LLC restated a “sell” rating and issued a $52.00 price objective on shares of Merck & in a research report on Sunday, August 20th. BMO Capital Markets restated a “buy” rating and issued a $72.00 price objective on shares of Merck & in a research report on Friday, September 8th. Credit Suisse Group decreased their target price on Merck & from $75.00 to $74.00 and set an “outperform” rating on the stock in a research report on Wednesday, August 30th. BidaskClub lowered Merck & from a “hold” rating to a “sell” rating in a research report on Tuesday, July 11th. Finally, Cowen and Company reiterated a “hold” rating and set a $70.00 target price on shares of Merck & in a research report on Friday, September 1st. Two analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $67.07.
TRADEMARK VIOLATION WARNING: “Checchi Capital Advisers LLC Sells 185 Shares of Merck & Company, Inc. (MRK)” was published by Community Financial News and is owned by of Community Financial News. If you are accessing this piece on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this piece can be read at https://www.com-unik.info/2017/11/04/checchi-capital-advisers-llc-sells-185-shares-of-merck-company-inc-mrk.html.
Shares of Merck & Company, Inc. (NYSE MRK) opened at $56.06 on Friday. The company has a market capitalization of $151.45 billion, a PE ratio of 14.23, a price-to-earnings-growth ratio of 2.38 and a beta of 0.78. The company has a quick ratio of 1.21, a current ratio of 1.50 and a debt-to-equity ratio of 0.55.
Merck & (NYSE:MRK) last issued its earnings results on Friday, October 27th. The company reported $1.11 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.03 by $0.08. Merck & had a return on equity of 26.82% and a net margin of 11.60%. The business had revenue of $10.33 billion during the quarter, compared to the consensus estimate of $10.54 billion. During the same period last year, the company earned $1.07 EPS. The company’s revenue for the quarter was down 2.0% on a year-over-year basis. research analysts predict that Merck & Company, Inc. will post 3.95 EPS for the current year.
Merck & Company Profile
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Company, Inc. (NYSE:MRK).
What are top analysts saying about Merck & Company Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Merck & Company Inc. and related companies.